Drugs / Mocertatug rezetecan
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06431594 | Jul 2024 → Sep 2027 expected | neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07694427 | Oct 2026 → Sep 2029 expected | ovarian neoplasm | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07684612 | Sep 2026 → May 2030 expected | ovarian neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT07684599 | Sep 2026 → Jul 2029 expected | endometrial cancer | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07286266 | Jun 2026 → Dec 2029 expected | ovarian neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT07286331 | Jun 2026 → Feb 2028 expected | endometrial cancer | GlaxoSmithKline | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-12 | GlaxoSmithKline | Results GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers gsk.com ↗
GSK plc (LSE/NYSE: GSK) today announced positive findings from its global phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. |
| 2026-03-02 | Hansoh BioMedical R&D Company | Results ESGO 2026 | 翰森制药Mocertatug Rezetecan（B7-H4 ADC）治疗铂敏感复发卵巢癌研究数据发布，其中一项研究入选LBA hansoh.cn ↗
Mocertatug rezetecan作为单药治疗及与贝伐珠单抗联合用药，在重度经治的铂敏感复发卵巢癌（PSOC）患者中显示出抗肿瘤活性，安全性可控. |
| 2026-02-28 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results ESGO 2026 | HANSOH PHARMA PRESENTED DATA FOR MOCERTATUG REZETECAN (HS-20089,A B7-H4-TARGETED ADC) IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER,WITH ONE STUDY SELECTED AS LBA hspharm.com ↗
Across the two studies, mocertatug rezetecan showed anti-tumor activity with a safety profile consistent with previous studies. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-12 | GlaxoSmithKline | GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers gsk.com ↗ |
| 2026-03-02 | Hansoh BioMedical R&D Company | ESGO 2026 | 翰森制药Mocertatug Rezetecan（B7-H4 ADC）治疗铂敏感复发卵巢癌研究数据发布，其中一项研究入选LBA hansoh.cn ↗ |
| 2026-02-28 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | ESGO 2026 | HANSOH PHARMA PRESENTED DATA FOR MOCERTATUG REZETECAN (HS-20089,A B7-H4-TARGETED ADC) IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER,WITH ONE STUDY SELECTED AS LBA hspharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mocertatug rezetecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07286266 ↗ |
| Known as | Mo-Rez | “This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) alone or in combination with bevacizumab works in treating ovarian cancer compared to...” NCT07694427 ↗4“This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care.” NCT07286331 ↗ “mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer” NCT07684612 ↗ “This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer” NCT07286266 ↗ “mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy” NCT07684599 ↗ |